Arcturus Therapeutics Holdings Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1.8% | 3.2% | 2.8% | 2.0% | 2.3% | 3.9% | – | – | 19.5% | 22.1% | 107.9% | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 80.5% | 100.0% | -7.9% | 100.0% | 83.2% | |
| 117.8% | 146.0% | 164.3% | 127.6% | 100.8% | 208.5% | 118.8% | 120.7% | 135.6% | 794.4% | 3,430.3% | 591.9% | 362.1% | |
| 30.8% | 49.9% | 45.6% | 26.8% | 34.2% | 59.0% | 38.5% | 42.2% | 60.6% | 455.3% | 1,551.6% | 371.4% | 188.6% | |
| 144.5% | 172.9% | 193.3% | 146.0% | 127.7% | 259.0% | 157.3% | 147.4% | 176.8% | 1,116.1% | 4,874.1% | 963.3% | 516.6% | |
| -44.5% | -72.9% | -93.3% | -46.0% | -27.7% | -159.0% | -57.3% | -47.4% | -96.3% | -1,016.1% | -4,882.0% | -863.3% | -433.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| -35.3% | -45.6% | -81.1% | -37.8% | -18.3% | -142.9% | -47.9% | -37.4% | -78.4% | -943.9% | -4,420.3% | -803.8% | -391.9% | |
| 2.1% | 1.0% | 1.1% | -0.3% | -0.6% | 0.0% | -57.3% | 0.0% | -97.3% | -0.1% | – | – | – | |
| -37.4% | -46.7% | -82.3% | -37.4% | -17.8% | -142.9% | -47.9% | -37.5% | -78.4% | -943.8% | -4,420.3% | -803.8% | -391.9% | |
| -33.4% | -42.4% | -78.4% | -35.8% | -16.0% | -139.0% | -45.2% | -34.3% | -74.0% | -653.7% | -4,312.5% | -803.8% | -348.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.